X‑Chem Expands Collaboration with Janssen in Inflammatory Diseases
WALTHAM, Mass. – February 15, 2017 – X-Chem, Inc. (X-Chem) announced today that it has expanded its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new drug leads for the treatment of inflammatory disease. The multi-target expansion builds on the parties’ existing discovery and license partnership, entered into in December 2014, and was facilitated by Johnson & Johnson Innovation. This latest agreement will apply X-Chem’s DEX™ platform to the identification of novel modulators for challenging disease targets, following the licensing of multiple series of X-Chem-discovered small molecules by Janssen in 2016. Under the terms of the agreement, X-Chem receives upfront payment and research funding, and is eligible to receive additional payments and royalties based on the achievement of clinical, regulatory and commercial milestones.
X‑Chem Acquires Glamorous AI — Immediately Creating a Leader in DEL-Powered AI Solutions
Combination Accelerates Outcomes in Early Drug Discovery WALTHAM, Mass.; Oct. 28, 2021 – X-Chem, the pioneer of DNA-encoded library (DEL)...
Getting Back to In Person
I recently had the pleasure of taking a trip to the West Coast to meet with several X-Chem clients. They...
Who We Are
English French X-Chem Is Your Partner in Small Molecule Drug Discovery X-Chem is the partner you need to unlock exponential...
Fibrolamellar Cancer Foundation: New research collaboration with X‑Chem
FCF is pleased to announce the establishment of a research collaboration with X-Chem, a global leader in DNA-encoded library (DEL) technology. Through...
A Year of Driving Small Molecule Discovery
2022 was a big year here at X-Chem, so as we embark into 2023 it seems like a good time...
The Importance of Selecting the Right CRO Partners for Drug Discovery Success
When it comes to drug discovery and development, having the right team and partners is critical for success. For a...
X‑Chem Enters into Multitarget Oncology Discovery Research Collaboration and License Agreement with Genentech
Collaboration Includes Licensing of Preclinical Small Molecule Program WALTHAM, Mass.; Feb. 2, 2021 (Business Wire) – X-Chem, Inc., a global...
X‑Chem Announces Licensing of 50th Drug Discovery Program
WALTHAM, Mass. – July 26, 2018 – X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEXTM) library drug discovery engine to the generation of novel small molecule therapeutics, today announced that it has licensed its 10th drug discovery program to date in 2018, bringing the total number of licensed programs to 50 since it launched its first target-based drug discovery partnership in 2012.
X‑Chem Enters Strategic Collaboration with Bristol-Myers Squibb
WALTHAM, Mass. – December 18, 2018 – X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEX™) library drug discovery engine to the generation of novel small molecule therapeutics, today announced the signing of a broad strategic drug discovery collaboration with Bristol-Myers Squibb.